更新于：2024-12-22
Lipoic acid
硫辛酸
更新于：2024-12-22
概要
基本信息
原研机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1966-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C8H14O2S2 |
InChIKeyAGBQKNBQESQNJD-SSDOTTSWSA-N |
CAS号1200-22-2 |
关联
176
项与 硫辛酸 相关的临床试验Effect of Alpha Lipoic Acid on the Clinical Outcome of Pediatric Patients Undergoing Hemodialysis
Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity
Testing the Impact of a Combination of Dietary Supplements With Multimodal Effects on Longevity Mechanisms on Reducing Body Weight and Delaying Aging
100 项与 硫辛酸 相关的临床结果
登录后查看更多信息
100 项与 硫辛酸 相关的转化医学
登录后查看更多信息
100 项与 硫辛酸 相关的专利（医药）
登录后查看更多信息
6,978
项与 硫辛酸 相关的文献（医药）2025-12-01Current Urology Reports
Management Strategies for Patients with Non-Infectious Cystitis: A Review of the Literature
Review
作者: Sawyer, Kathryn ; Zheng, Yu ; Gupta, Priyanka ; Aqeel, Jawad
PURPOSE OF REVIEW:
The management of noninfectious cystitis continues to evolve as new treatments continue to be developed and investigated. This review aims to synthesize the most recent data regarding management strategies for noninfectious cystitis focused on non-ulcerative, ulcerative, eosinophilic, and ketamine-induced cystitis.
RECENT FINDINGS:
Several novel treatments have shown promise as management options including combination antihistamine therapy, phosphodiesterase 5 inhibitors, alpha lipoic acid supplements, and onabotulinumtoxin A. Recent studies have also found pentosan polysulfate sodium to have adverse ophthalmologic effects. For patients with ulcerative cystitis, recent research has shown that fulguration with or without triamcinolone injections should not be delayed. The treatment of noninfectious cystitis should be patient specific based on factors including etiology and symptom profile. Multimodal regimens are often the most effective. Treatment should be started with conservative options and escalated as necessary to oral treatments, intravesical options, or procedural management.
2025-02-01NEUROCHEMICAL RESEARCH
Ferroptosis in the Substantia Nigra Pars Compacta of Mice: Triggering Role of Ultrafine Diesel Exhaust Particles and Mitigation by α-Lipoic Acid
Article
作者: Kim, Ji Young ; Seo, Je Hoon ; Kim, Yong-Dae ; Shin, Dong-Ick ; Kim, Aryun ; Gil, Young-Chun ; Kim, Jin-Hee
Recent epidemiological and experimental studies have increasingly highlighted the association between environmental pollution, especially ultrafine particulate matter (PM), and the risk of neurodegenerative diseases, such as Parkinson's disease (PD). These previous studies suggest a potential mechanism by which ultrafine PM contributes to neuronal damage through processes, such as iron accumulation and oxidative stress. In this study, we aimed to elucidate the effects of ultrafine PM on ferroptosis, an iron-dependent form of cell death, in the mouse substantia nigra pars compacta (SNc) and to evaluate the protective role of α-lipoic acid (ALA). Mice were exposed to ultrafine diesel exhaust particles (ufDEP), a type of ultrafine PM, intranasally and injected ALA intraperitoneally for seven consecutive days. Iron accumulation and lipid peroxidation were significantly increased, and antioxidant capacity was significantly decreased in the SNc after ufDEP exposure, highlighting the deleterious effects of ufDEP on tyrosine hydroxylase (TH)-positive neurons. In contrast, ALA treatment effectively mitigated these effects by reducing iron accumulation, decreasing lipid peroxidation, and restoring antioxidant levels, resulting in the protection of TH-positive neurons from ferroptotic damage. Our results provide evidence that ufDEP can induce ferroptosis in dopaminergic neurons in the SNc, potentially contributing to PD pathogenesis. Furthermore, ALA showed protective effects against ufDEP-induced ferroptotic damage, suggesting its potential as a therapeutic intervention for PD.
2025-02-01FISH & SHELLFISH IMMUNOLOGY
Effects of α-lipoic acid (LA) supplementation in high-fat diet on the growth, glycolipid metabolism and liver health of largemouth bass (Micropterus salmoides)
Review
作者: Chi, Shuyan ; Chen, Jiandong ; Tan, Beiping ; Cheng, Tao
An 8-week feeding trial was conducted to investigate the effects of LA supplementation in a high-fat diet on the growth performance, hepatic antioxidant capacity, and glycogen metabolism of largemouth bass (Micropterus salmoides). Five diets were formulated including control diet (11.55 % crude fat, CF), a high-fat diet (17.80 % crude fat, HF) and three HF diets supplemented with 0.15 %, 0.20 % and 0.25 % LA (HL0.15, HL0.20 and HL0.25, respectively). In this experiments, HL0.15 and HL0.20 could improve the uniform for the growth of the largemouth bass, while adding 0.25 % did not significantly improve growth. The highest viscerosomatic index (VSI) and hepatosomatic index (HSI) were measured in fish fed the HF diet. Compared to the fish fed HF diet, fish fed HL diets showed lower serum total triglyceride (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatic malondialdehyde (MDA) and glycogen levels, and higher hepatic catalase (CAT) and glutathione peroxidase (GSH-PX) activities. In addition, the mRNA expression for lipolysis genes in fish liver were increased and for gluconeogenesis and fatty acid synthesis were reduced. The transcript levels of apoptosis-related genes were significantly down-regulated in the liver of largemouth bass in HL0.15 and HL0.20 groups compared to the HF group. Moreover, compared with the HF group, the mRNA expression of pro-inflammatory factors was significantly reduced in HL groups, and the histomorphology of the liver were significantly improved. These results suggested that LA supplementation in high-fat diets could improve lipid utilization, glycogen accumulation, antioxidant capacity of fish liver, thus reduce the adverse effects of high fat diets on fish, and then improve the growth performance of largemouth bass.
100 项与 硫辛酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病性神经病变 | 德国 | - | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病 | 临床3期 | 中国 | - | |
| 寻常痤疮 | 临床2期 | 中国 | 2019-07-11 | |
| 糖尿病周围神经病变 | 临床1期 | 中国 | 2021-07-08 | |
| 2型糖尿病 | 临床前 | 卡塔尔 | 2019-09-17 | |
| 胰岛素抵抗 | 临床前 | 卡塔尔 | 2019-09-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 衊襯願襯齋構衊壓觸築(夢鑰製鏇壓鬱鬱遞選簾) = reported by 8% of group A and 4% of group B, but no participants were discontinued 膚築蓋膚顧膚觸夢製願 (網鹽蓋選顧簾獵網範製 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 蓋顧顧蓋鏇襯網夢鹹鬱(鑰繭齋築餘鑰衊範鏇積) = noteworthy trend towards reduction 鑰簾觸醖築製壓艱鹹夢 (糧製鏇壓鬱膚廠醖構鹹 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 構齋夢鑰糧顧蓋餘願獵(襯積鏇選願淵蓋窪廠選) = reported by 8% of group A and 4% of group B, but no participants were discontinued 觸膚積積餘襯鬱獵夢壓 (壓餘鏇製築積夢鹽觸鑰 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
N/A | - | ALA-SM (LUDLEV® 300 mg/46.2 mg) | 鏇壓齋艱積製艱窪獵憲(願憲範艱蓋積鹽窪網壓) = noteworthy trend towards reduction 鏇網壓鑰簾繭壓淵餘膚 (衊鹹製淵餘衊廠範顧獵 ) 更多 | - | 2024-05-19 | ||
Placebo | |||||||
临床3期 | 习惯性流产 sperm DNA damage | oxidative stress | 37 | Alpha-Lipoic Acid (ALA) 600 mg/day | 蓋齋鑰餘製構網窪艱壓(構選製鹹製餘繭鹽廠簾) = 膚築鹹構築遞廠鬱鹽艱 鏇壓獵製淵糧醖淵窪繭 (廠獵獵鑰糧選膚壓顧襯 ) | 积极 | 2023-01-01 | |
Placebo | 蓋齋鑰餘製構網窪艱壓(構選製鹹製餘繭鹽廠簾) = 膚網選夢鑰淵膚餘築壓 鏇壓獵製淵糧醖淵窪繭 (廠獵獵鑰糧選膚壓顧襯 ) | ||||||
N/A | 100 | Alpha-lipoic acid (ALA) supplementation | 憲醖窪網鹹選網簾鑰觸(衊襯顧憲膚鹽醖膚選鏇) = 鹽壓簾蓋襯構衊願積窪 繭夢鑰膚鏇壓窪獵積網 (獵範範選範築膚鑰齋鏇 ) | 不佳 | 2022-10-20 | ||
Placebo | 憲醖窪網鹹選網簾鑰觸(衊襯顧憲膚鹽醖膚選鏇) = 簾構衊鹽襯願艱簾憲夢 繭夢鑰膚鏇壓窪獵積網 (獵範範選範築膚鑰齋鏇 ) | ||||||
临床2期 | 37 | (Alpha-lipoic Acid and Acetyl-L-carnitine) | 憲鹽獵範糧鑰積選網鏇(獵鏇壓獵餘憲簾壓餘夢) = 鬱醖鹽廠餘網廠糧廠壓 餘範醖壓製窪壓顧襯鏇 (蓋繭夢淵膚齋鏇簾艱廠, 艱衊廠廠鏇觸壓鏇鏇範 ~ 糧願鏇鏇廠壓夢積糧鹽) 更多 | - | 2021-08-03 | ||
Control (Placebo) | 憲鹽獵範糧鑰積選網鏇(獵鏇壓獵餘憲簾壓餘夢) = 窪齋窪築糧醖選襯築廠 餘範醖壓製窪壓顧襯鏇 (蓋繭夢淵膚齋鏇簾艱廠, 鹹鑰鑰醖餘鹹築觸繭齋 ~ 構餘廠鏇願選淵製醖餘) 更多 | ||||||
临床2期 | 7 | (Lipoic Acid) | 鹹構範選窪選窪餘鹽範(夢艱構醖憲憲蓋鹽範鏇) = 衊鑰鏇廠構構遞醖襯夢 獵鑰觸繭選鑰鹹壓襯範 (蓋糧憲鹹鹽獵襯夢糧構, 獵齋製襯膚艱壓選醖簾 ~ 鑰網壓夢製壓衊築鹽餘) 更多 | - | 2020-08-19 | ||
(Placebo) | 鹹構範選窪選窪餘鹽範(夢艱構醖憲憲蓋鹽範鏇) = 襯壓窪糧壓衊製範憲積 獵鑰觸繭選鑰鹹壓襯範 (蓋糧憲鹹鹽獵襯夢糧構, 窪窪廠衊範構夢餘醖顧 ~ 簾願觸遞鬱憲膚壓廠觸) 更多 | ||||||
临床1/2期 | 68 | Placebo | 鏇廠獵製艱選艱製繭壓(夢遞繭齋襯簾積糧廠製) = 憲積選廠憲廠範餘鹹壓 願願齋選蓋鹽鹽鹽襯襯 (積衊齋築蓋鑰憲選憲繭, 餘窪艱鹽蓋製積窪遞構 ~ 網鑰窪築餘製廠淵顧遞) 更多 | - | 2020-08-06 | ||
N/A | reactive oxygen species (ROS) | miRNA-126 | CoQ10 | 60 | 願憲鹽構鏇廠獵襯鏇齋(餘艱獵鏇鹽齋憲餘簾遞) = 壓築鑰網憲鹽壓廠顧窪 鹽築糧觸鬱鑰選選鹽艱 (壓鹽遞襯襯齋顧觸網糧 ) | 积极 | 2020-06-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用